Immune responses to vaccines delivered by encapsulation into and/or adsorption onto cationic lipid PLGA hybrid nanoparticles.
In this study, we used cationic lipid poly(lactide co glycolide) acid (PLGA) hybrid nanoparticles as antigen delivery carriers to investigate how antigen loading methods affect antigen exposure to the immune system and evaluated the resulting antigen specific immune responses. We formulated three classes of antigen adsorbed and/or encapsulated cationic lipid PLGA hybrid nanoparticles; we designated antigen adsorbed (out) antigen encapsulated (in) and antigen adsorbed/encapsulated (both) nanoparticles. Our results demonstrate significantly more efficient lysosomal escape and cross presentation of antigen from dendritic cells (DCs) that were exposed to "both" and "in" nanoparticles. In vivo experiments further revealed that "both" nanoparticles significantly more effectively provided not only adequate initial antigen exposure but also long term antigen persistence at the injection site. Data from flow cytometry and ELISA analyses demonstrated elevated in vivo immune responses from mice that were immunized with nanoparticles delivered OVA when compared with free OVA. In addition, "in" and "both" nanoparticles elicited significantly higher antigen specific immune response than "out" nanoparticles and free OVA. These results suggest that the location of antigen entrapment is an important factor in modulating the immune responses of antigens delivered by nanoparticles. Overall, we propose here a promising approach for the future design of vaccines using cationic lipid PLGA nanoparticles.
Journal of controlled release official journal of the Controlled Release Society